Tellgen

Tellgen Cash Flow per Share

The Operating Cash Flow per Share of Tellgen (300642.SZ) as of Oct 25, 2026 is 0.88 CNY. In the previous year, Operating Cash Flow per Share was 1.02 CNY — a change of -13.19% (lower).

Cash Flow per Share

0.88CNY

YoY

-13.19%

Last updated:

Operating Cash Flow per Share of Tellgen is 2025 0.88 CNY. Operating Cash Flow per Share of Tellgen was 2024 1.02 CNY. It decreases by -13.19% lower compared to the previous year.

The Tellgen Cash Flow per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Flow per Share
Date
Cash Flow per Share
Jan 1, 2018
1.02 CNY
Jan 1, 2019
1.07 CNY
Jan 1, 2020
0.60 CNY
Jan 1, 2021
0.49 CNY
Jan 1, 2022
1.02 CNY
Jan 1, 2023
0.78 CNY
Jan 1, 2024
1.02 CNY
Jan 1, 2025
0.88 CNY
The Tellgen Cash Flow per Share history
YEARCash Flow per ShareYoY
0.88CNY-13.19%
1.02CNY+30.94%
0.78CNY-23.67%
1.02CNY+106.00%
0.49CNY-17.96%
0.60CNY-43.64%
1.07CNY+4.68%
1.02CNY+57.47%
0.65CNY-19.42%
0.81CNY+51.98%
0.53CNY+110.40%
0.25CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tellgen Stock analysis

What does Tellgen do? Tellgen Corp develops, manufactures, and markets molecular diagnostic products including immunodiagnostic, molecular diagnostic, and biochemical diagnostic products. Their portfolio features tumor marker detection, HPV nucleic acid testing, autoimmune disease detection, and lung cancer methylation mutation detection products. The company targets healthcare providers and laboratories seeking advanced diagnostic solutions for disease detection and monitoring. Tellgen Corp generates revenue through the sale of these specialized diagnostic products to medical institutions and healthcare facilities. The firm's product lines focus on specific diagnostic needs such as cancer screening and infectious disease testing. Immunodiagnostic products detect antibodies and antigens, molecular diagnostic products analyze genetic material, and biochemical diagnostic products measure metabolic markers. Tellgen Corp sells these products directly to hospitals, clinics, and diagnostic laboratories across China and potentially internationally. Tellgen Corp's revenue streams come from the commercialization of its diagnostic product portfolio. The company's offerings address key healthcare challenges including early cancer detection and infectious disease management. Their products are designed to support clinical decision-making and patient care pathways in medical settings. Tellgen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tellgen stock

Operating Cash Flow per Share of Tellgen is 0.88 CNY in 2025.

Operating Cash Flow per Share of Tellgen changed from 1.02 CNY to 0.88 CNY, representing a -13.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow per Share Tellgen since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow per share measures the operating cash generated per outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Tellgen

All Key Metrics — Tellgen